South Jordan, UT, United States of America

Adam Siddiqui-Jain

This inventor holds 25 USPTO granted patents and 13 published patent applications and 5 EPO patents, primarily in Cancer Treatment. Top assignees: Sumitomo Pharma Oncology, Inc., Tolero Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Oncology, Inc.. Active years: 2017-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adam Siddiqui-Jain. Retrieved from https://idiyas.com/inventor/adam-siddiqui-jain

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 13)

% Patents Active = 88.0

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 2.7

ph-index = 7

Forward Citations = 130(Granted Patents)

Location History:

Lehi, UT (US) (2020)
South Jordan, UT (US) (2017 - 2024)

Company Filing History:

8 out of 11

Sumitomo Pharma Oncology, Inc.

patents

8 out of 21

Tolero Pharmaceuticals, Inc.

patents

5 out of 11

Sumitomo Dainippon Pharma Oncology, Inc.

Years Active: 2017-2025

Loading Chart...

Areas of Expertise:

Cancer

Alvocidib

CDK9 Inhibitors

AXL Kinase

Antimitotic Amides

Proliferative Disorders

Tyrosine Kinase

Combination Therapies

Bioavailability

Heterocyclic Inhibitors

Sensitivity Profiling

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383533 - Antimitotic amides for the treatment of cancer and proliferative disorders (2025-08-12),

2. 12338261 - Alvocidib prodrugs having increased bioavailability (2025-06-24),

3. 12077554 - CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer (2024-09-03),

4. 11746103 - ALK-5 inhibitors and uses thereof (2023-09-05),

5. 11530231 - CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer (2022-12-20),

6. 11529350 - Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof (2022-12-20),

7. 11497756 - Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib (2022-11-15),

8. 11471456 - Formulations comprising heterocyclic protein kinase inhibitors (2022-10-18),

9. 11400091 - AXL kinase inhibitors and use of the same (2022-08-02),

10. 11279694 - Alvocidib prodrugs and their use as protein kinase inhibitors (2022-03-22),

11. 11129813 - Antimitotic amides for the treatment of cancer and proliferative disorders (2021-09-28),

12. 11040038 - Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same (2021-06-22),

13. 11034710 - CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer (2021-06-15),

14. 11013741 - AXL kinase inhibitors and use of the same (2021-05-25),

15. 10835537 - Combination therapies for treatment of cancer (2020-11-17),

Title: Adam Siddiqui-Jain: Pioneering Innovation for a Sustainable Future

Introduction: Adam Siddiqui-Jain, a dedicated inventor based in South Jordan, UT (US), is recognized for his commitment to pushing the boundaries of technology and creating a more sustainable future. With 22 patents to his name, including groundbreaking inventions in the field of pharmaceuticals, Adam is a true pioneer in the world of innovation.

Latest Patents: Among Adam Siddiqui-Jain's latest patents are ALK-5 inhibitors and uses thereof, which are compounds designed for treating and preventing diseases such as cancer by inhibiting tumor growth. Additionally, his CDK9 inhibitors and polymorphs offer new possibilities for cancer treatment, showcasing his versatility in invention.

Career Highlights: Adam Siddiqui-Jain has made significant contributions to the pharmaceutical industry through his work at Tolero Pharmaceuticals, Inc. and Sumitomo Pharma Oncology, Inc. His innovative approaches have led to the development of cutting-edge solutions for treating proliferative diseases and inhibiting tumor growth.

Collaborations: Throughout his career, Adam has collaborated with esteemed professionals in the industry, including David J Bearss and Steven L Warner. Their combined expertise and shared passion for innovation have driven forward-thinking research and development initiatives.

Conclusion: Adam Siddiqui-Jain's inventive spirit, dedication to sustainability, and collaborative approach set him apart as a visionary inventor. His ability to think creatively and strive for excellence continues to inspire others in the industry, making him a true leader in the world of innovation.

Profile summary based on public USPTO records.